In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:

Optimal testing for RET fusions
DNA NGS vs RNA NGS
Molecular testing workflows
Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
Common toxicities with new selective RET inhibitors
Interdisciplinary communication between medical oncologists and pathologists

Presenters:
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program, including associated downloadable slidesets:
https://bit.ly/2Fsq9Wv

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Clinical Considerations for <em>RET</em> Fusion–Positive NSCLC